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commissural morphology
Conclusion: We concluded that commissural opening degree and mitral valve area are
closely related. The degree of commissural opening provides important prognostic
information, and complete commissural opening is associated with better late
functional results. Thus, degree of commissural opening should be systematically
evaluated during and after balloon mitral comissurotomy and can be considered as a
complementary measure of the procedural success in addition to the mitral valve area.
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Background: Transcatheter implantation of the MitraClip (MC; Abbott, Abbott Park,
IL) has evolved as a viable option to treat moderate/severe mitral regurgitation (MR).
The recent EVEREST II trial suggested that elderly patients (pts) with functional MR
and impaired LV function may particularly benefit from this therapeutic approach.
Methods: We studied 69 consecutive pts with functional MR (73 ± 8 years; 46 men
[67%]) who were attested a prohibitive surgical risk (median EuroSCORE 33%) by
joint (“heart team”) consensus of cardiovascular surgeons and cardiologists. Baseline
MR grade was 3+ (n=37) or 4+ (n=32) and mean LVEF was 37 ± 13%; all pts were in
NYHA functional class III or IV. Exclusion criteria of EVEREST trials were met in 56
pts (81%). All pts underwent MC therapy as previously described.
Results: Device success (residual MR ≤2+) was achieved in 66 pts (96%), with ≥2
clips implanted in 21 pts (30%). At discharge, 39 pts had MR 2+ and 27 had MR 1+.
Clinical and echocardiographic follow-up (FU) at 373 days (median) was obtained
from 57 and 44 pts, respectively. Functional improvement was noted in 43/57 pts
(75%), with 37/57 pts (64%) in NYHA class I or II. Six-minute walk distance improved
in 27/39 pts (69%) by 105 m – a 50% increase – and the Minnesota quality-of-life
score improved by -18 points – a 43% decrease – in 25/37 pts (68%). At FU, MR grade
was improved over baseline in 89% of pts (39/44); 80% of pts (35/44) had MR 1+ or
2+. LV end-diastolic and end-systolic volumes decreased significantly (median 210
vs. 239 ml [p<0.0001] and 127 vs. 136 ml [p=0.0012], respectively), whereas forward
stroke volume increased (median 49 vs. 42 ml [p=0.0005]). Kaplan-Meier 1-year
estimates of survival free from rehospitalization for cardiac decompensation and
survival free from death, rehospitalization or reintervention were 64.5% and 48.8%,
respectively.
Conclusion: MC therapy is feasible and efficacious in elderly pts with functional MR
not amenable to surgery who mostly would have been excluded from EVEREST. Thus,
MC implantation evolves as a novel treatment strategy in heart failure patients with
concomitant MR.
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Background: Few reports demonstrated that increased inflammatory markers as well
as platelet, coagulation, fibrinolytic activities in mitral stenosis (MS) decrease after
percutaneous mitral valvotomy (PMV). The relationship between the inflammatory
markers and platelet, coagulation, and fibrinolytic activities was not studied before.
Methods: The study included 65 patients with MS undergoing PMV, and 23 controls.
Markers of platelet activity (P-Selectin), thrombin activity (Prothrombin fragment1,2
“PF1,2” and thrombin antithrombin complex “TAT”), fibrinolysis (D-Dimer), and
inflammation (interleukin 1B “IL1B”) were measured from venous samples obtained
before and 2 weeks after PMV and in all controls.
Results: All hemostatic and inflammatory markers were significantly higher in MS
patients than the control and they significantly decreased after PMV. Only in PF1,2
the level became not significantly different from the control after PMV. The change in
any of these variables didn’t correlate with the change in mitral valve area, mean
transmitral pressure gradient, left ventriculat dimensions and function. P-selectin
change was predicted by the changes in left atrial diameter “LAd” (r 0.4, P 0.02),
pulmonary artery systolic pressure “PASP” (r 0.3, P 0.02) and IL1B (r 0.7, P <0.0001).
D-dimer change had similar predictors; LAd (r 0.5, P <0.0001), PASP (r 0.3, p 0.04),
and IL1B (r 0.5, P <0.0001). PF1,2 change was predicted with the change in IL1B (r
0.8, P <0.0001). TAT change was predicted by the changes in LAd (0.3, P 0.02) and
right ventricular diameter “RVd” (r 0.3, P 0.04). IL1B change was predicted with the
changes in aortic root diameter (0.4, p 0.02), RVd (r 0.5, P 0.04), and PASP (r 0.5, P
0.03).
Conclusion: MS is associated with heightened inflammatory, platelet, thrombin, and
fibrinolytic activities that decrease after PMV. Altered hemodynamics might play a
possible role in some of these changes. Reduced inflammatory activity might have a
role in reduced platelet, thrombin, and fibrinolytic activities after PMV.
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Background: Treatment of high surgical risk patients with significant functional mitral
regurgitation (FMR) is an important clinical challenge, as surgical correction of MR
may not always be a feasible option. The purpose of this analysis is to describe the
clinical benefit, including improvements in LV function and clinical symptoms,
observed following treatment with the MitraClip device in high surgical risk patients
with FMR.
Methods: EVEREST II High Surgical Risk Trial patients had significant MR (3+ or
4+) and were deemed high risk for surgery as predicted by a STS risk calculator
operative mortality of ≥ 12%, or surgeon assessment. Clinical outcomes included
NYHA Class, quality of life (QOL) measures, and echocardiographic measurements
by an independent core lab.
Results: 149 high surgical risk FMR patients underwent a MitraClip procedure with a
96% implant rate. A majority had prior cardiac surgery (63%), prior MI (57%) and
mean predicted surgical mortality by STS calculator of 11.3 ± 7.0%. Mortality at 30
days and 1 year was 5.4% and 23.9%, respectively. Of remaining patients with data at
baseline and 1 year, 101 had NYHA Class and 89 had matched echocardiograms, of
which 80% (71/89) achieved MR severity of 2+ or less. Significant improvements in
LV volumes, NYHA Class, and QOL (Table) were observed at 1 year.
Conclusion: The MitraClip procedure resulted in significant improvements in MR
severity, ventricular remodeling, and clinical outcomes and is an important therapeutic
option for select patients with significant functional MR who are at high risk for
surgical mortality.
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Background: The effect of Percutaneous Mitral Valvotomy (PMV) on longitudinal
left and right ventricular systolic and diastolic functions assessed by pulsed-wave
tissue-Doppler imaging (PW-TDI) was not studied well before.
Methods: The study included 52 patients with mitral stenosis (age 26±8 years, 16
“32%” males, score 6.8±1.2, mitral valve area ≤1.5cm2, mitral regurgitation ≤ II/IV).
Longitudinal right and left ventricular functions were assessed before and 2 weeks
after PMV by PW-TDI. PW-TDI measurments of the septal, anterior, lateral and
inferior mitral annulus were taken as measurments of the longitudinal left ventricular
functions. Also, PW-TDI measurments at the lateral tricuspid annulus were taken as
measurments of the longitudinal right ventricular functions.
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